STRYKER CORPORATION (NYSE:SYK) Files An 8-K Regulation FD Disclosure

STRYKER CORPORATION (NYSE:SYK) Files An 8-K Regulation FD Disclosure
ITEM 7.01

Story continues below


While it is Stryker Corporation's (Stryker) longstanding practice not to comment on these matters, today Stryker issued the following statement in response to the market speculation about a proposal to acquire Boston Scientific Corporation: "Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition."

The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties. The Company’s Neurotechnology and Spine segment products consist of both neurosurgical and neurovascular devices. The Company’s products are sold in approximately 100 countries through the Company-owned sales subsidiaries and branches, as well as third-party dealers and distributors.

An ad to help with our costs